Full-Time

Account Specialist

Anti Infectives

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$78.5k - $192.5k/yr

+ Short-Term Incentive

Denver, CO, USA

Remote

Must live within reasonable distance of Denver, CO.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelor’s degree in health, sciences, pharmacy or business-related field or relevant and equivalent industry experience required
  • If no bachelor’s degree, at least five years of experience with three or more years of experience within the pharmaceutical/health/science industry preferred and a high school diploma/GED required
  • Account based selling experience (Hospitals, Wound Care Centers, or Infusion Centers) and experience building advocacy in hospitals, with or without a formulary win, for acute products
  • Knowledge of formulary approval process and driving formulary approvals
  • Experience with Buy and Bill and specialty pharmacy products is preferred
  • Documented history of strong sales performance, consistent top performer, in a challenging market space or product portfolio; proven advanced sales skills and ability to communicate complex products while overcoming customer concerns
  • Strong business acumen including ownership of sales geography, multitasking, data analysis with multiple tools, and ability to define account/program strategies
  • Strong planning and organization skills; strong presentation and facilitation skills; ability to learn procedural, technical, and clinical information quickly; ability to present complex scientific information to varied audiences
  • Ability to influence others and build collaborative partnerships; credible resource among peers; ability to fully cover the assigned geography
  • Valid driver’s license and ability to pass pre-employment drug screening; meet safe driving requirements
  • Ability to travel adequately to cover territory and attend training; overnight travel implied
  • HCIR credentialing requirements to gain and maintain entry into facilities and organizations in territory; includes background checks, drug screens, immunization proof, fingerprinting, licenses as required by state/city
Responsibilities
  • Advances hospital and specialty customers along the sales continuum and gains prescriber commitments through effective questioning, active listening, and utilization of approved data and resources; delivers on-label presentations/sales calls to highlight benefits and risks of the product portfolio to create awareness of product solutions and address gaps in therapeutic areas, resulting in sales goal achievement
  • Develops professional relationships and differentiates the Anti-Infective portfolio’s value proposition at all levels within accounts and departments to further the use of the product portfolio
  • Strong understanding and ability to problem solve product and patient flow through Specialty Pharmacy, Specialty Distribution, and Buy and Bill channels; coordinate and mobilize key stakeholders across multiple departments with competing goals to align individuals on patient focused solutions
  • Uses opportunities to understand and address customer needs; builds strong relationships that provide market intelligence and support development of compliant and innovative programs and initiatives
  • Builds and maintains relationships across accounts that result in opportunities to benefit patients, physicians, and other HCPs within the geography
  • Ability to succeed in a complex, matrixed, account-based selling environment; collaborates with AbbVie in-field and in-house teams to design/adapt approaches and tactics
  • Creates, develops, executes, and monitors strategic geography business plans; determines department, channel, HCP focus and frequency by account to meet sales objectives; aligns resources to support tactics
  • Sources, interprets and utilizes key data by account to develop and maintain working account profiles and relationship maps; targets key stakeholders within each setting to expand usage and customer base
  • Attend and participate in local boards, societies, conventions, and HCP meetings; represent AbbVie; channel key information to internal partners; all communications in these forums are on-label
  • Complete AbbVie required training and maintain adherence to policies and credentialing requirements including HCIR; health care industry representative credentialing may include background checks, drug screens, immunizations, fingerprinting and licenses
  • Proactively collaborates across multiple departments; works with cross-functional partners and Medical Science Liaisons to develop compliant communication strategies
Desired Qualifications
  • Experience with Buy and Bill and specialty pharmacy products is preferred

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.